David Wayne Nichols - Apr 19, 2021 Form 4/A - Amendment Insider Report for Magenta Therapeutics, Inc. (MGTA)

Role
Chief Technical Officer
Signature
/s/ Cindy Driscoll, Attorney-in-Fact for David Nichols
Stock symbol
MGTA
Transactions as of
Apr 19, 2021
Transactions value $
$0
Form type
4/A - Amendment
Date filed
5/17/2021, 05:07 PM
Date Of Original Report
Apr 20, 2021
Next filing
Sep 16, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGTA Stock Option (Right to Buy) Award $0 +175K $0.00 175K Apr 19, 2021 Common Stock 175K $10.50 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exerciseable over four years, with 25% of this option vesting on April 19, 2022, and the remainder vesting in 36 equal monthly installments thereafter.
F2 This amendment has been filed to revise the vesting terms of Mr. Nichols' stock option, which were reported incorrectly on Mr. Nichols' prior Form 4. The corrected vesting schedule is included in Footnote 1 above.